Main results of the Ouabain and Adducin for Specific Intervention on Sodium in Hypertension Trial (OASIS-HT): A randomized placebo-controlled phase-2 dose-finding study of rostafuroxin

Trials

Volumn 12, Issue , 2011, Pages

  Staessen, Jan A ^a,b   Thijs, Lutgarde ^a   Stolarz Skrzypek, Katarzyna ^c   Bacchieri, Antonella ^d   Barton, John ^e   Espositi, Ezio D ^f   de Leeuw, Peter W ^g   Dłuzniewski, Mirosław ^h   Glorioso, Nicola ⁱ   Januszewicz, Andrzej ^j   Manunta, Paolo ^k   Milyagin, Viktor ^l   Nikitin, Yuri ^m   Souček, Miroslav ⁿ   Lanzani, Chiara ^k   Citterio, Lorena ^k   Timio, Mario ^o   Tykarski, Andrzej ^p   Ferrari, Patrizia ^q   Valentini, Giovanni ^d   Kawecka Jaszcz, Kalina ^c   Bianchi, Giuseppe ^k   more..

^a UNIVERSITY OF LEUVEN   (Belgium)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^d Sigma Tau SpA   (Italy)

^e Portiuncula Hospital   (Ireland)

^f Laboratory of Clinical Pharmacology and Toxicology   (Italy)

^g MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^h Postgraduate Medical School ^*  (Poland)

ⁱ UNIVERSITY OF SASSARI   (Italy)

^j MEDICAL UNIVERSITY OF WARSAW   (Poland)

^k SAN RAFFAELE HOSPITAL   (Italy)

^l SMOLENSK STATE MEDICAL UNIVERSITY   (Russian Federation)

^m INSTITUTE OF PHYSIOLOGY   (Russian Federation)

ⁿ ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

^o Ospedale S Giovanni Battista   (Italy)

^p POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^q Prassis Sigma Tau Research Institute   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADDUCIN; ALDOSTERONE; OUABAIN; PLACEBO; PST 1138; RENIN; ROSTAFUROXIN; SODIUM; UNCLASSIFIED DRUG; 17 (3 FURYL) 5BETA ANDROSTANE 3,14,17 TRIOL; 17-(3-FURYL)-5BETA-ANDROSTANE-3,14,17-TRIOL; ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ANDROSTANE DERIVATIVE; ANTIHYPERTENSIVE AGENT; CALMODULIN BINDING PROTEIN;

ADULT; ARTICLE; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART PALPITATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE; OTITIS; PHASE 2 CLINICAL TRIAL; PLASMA RENIN ACTIVITY; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SKIN TOXICITY; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; UNCONSCIOUSNESS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; UROGENITAL TRACT MALFORMATION; XEROSTOMIA; BLOOD; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ANTAGONISM; EUROPE; GENETICS; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; MUTATION; PATHOPHYSIOLOGY; TIME; URINE;

ADULT; ALDOSTERONE; ANDROSTANOLS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CALMODULIN-BINDING PROTEINS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; EUROPE; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MUTATION; OUABAIN; RENIN; SODIUM; SODIUM-POTASSIUM-EXCHANGING ATPASE; TIME FACTORS; TREATMENT OUTCOME;

EID: 78651354653     PISSN: 17456215     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-12-13     Document Type: Article

References (20)

1. Quadri L, Bianchi G, Cerri A, Fedrizzi G, Ferrari P, Gobbini M, Melloni P, Sputore S, Torri M. 17β-(3-furyl)-5β-androstane-3β,14β,17α-triol (PST 2238). A very potent antihypertensive with a novel mechanism of action. J Med Chem 1997, 40:1561-1564. 10.1021/jm970162e, 9171865.
2. Ferrari P, Ferrandi M, Tripodi G, Torielli L, Padoani G, Minotti E, Melloni P, Bianchi G. PST 2238: a new antihypertensive compound that modulates Na,K-ATPase in genetic hypertension. J Pharmacol Exp Ther 1999, 288:1074-1083.
3. Staessen JA, Kuznetsova T, Acceto R, Bacchieri A, Brand E, Burnier M, Celis H, Citterio L, de Leeuw PW, Filipovský J, et al. Ouabain and Adducin for Specific Intervention on Sodium in HyperTension (OASIS-HT): design of a pharmacogenomic dose-finding study. Pharmacogenomics 2005, 6:755-775. 10.2217/14622416.6.7.755, 16207152.
4. Ferrari P, Ferrandi M, Valentini G, Bianchi G. Rostafuroxin: an ouabain antagonist that corrects renal and vascular Na+-K+-ATPase alterations in ouabain and adducin-dependent hypertension. Am J Physiol Regul Integr Comp Physiol 2006, 290:R529-R535.
5. 41st World Medical Assembly Declaration of Helsinki: recommendations guiding physicians in biomedical research involving human subjects. Bull Pan Am Health Organ 1990, 24:606-609. 41st World Medical Assembly.
6. Ferrari P, Ferrandi M, Torielli L, Tripodi G, Melloni P, Bianchi G. PST2238: a new antihypertensive compound that modulates Na+,K+-ATPase and antagonizes the pressor effect of OLF. Cardiovasc Drug Rev 1999, 17:39-57.
7. European Society of Hypertension/European Society of Cardiology Guidelines Committee 2003 European Society of Hypertension/European Society of Cardiology Guidelines for the Management of Arterial Hypertension. J Hypertens 2003, 21:1011-1053. 10.1097/00004872-200306000-00001, 12777938, European Society of Hypertension/European Society of Cardiology Guidelines Committee.
8. Kuznetsova T, Staessen JA, Kawecka-Jaszcz K, Babeanu S, Casiglia E, Filipovský J, Nachev C, Nikitin Y, Peleška J, O'Brien E, et al. Quality control of the blood pressure phenotype in the European Project on Genes in Hypertension. Blood Press Monit 2002, 7:215-224. 10.1097/00126097-200208000-00003, 12198337.
9. O'Brien E, Mee F, Atkins N, O'Malley K. Accuracy of the SpaceLabs 90207 determined by the British Hypertension Society Protocol. J Hypertens 1991, 9(suppl 5):S25-S31.
10. Fagard R, Brguljan J, Thijs L, Staessen J. Prediction of the actual awake and asleep blood pressures by various methods of 24 h pressure analysis. J Hypertens 1996, 14:557-563. 10.1097/00004872-199605000-00003, 8762197.
11. Thijs L, Staessen J, Fagard R. Analysis of the diurnal blood pressure curve. High Blood Press 1992, 1:17-28.
12. Tikhonoff V, Kuznetsova T, Stolarz K, Bianchi G, Casiglia E, Kawecka-Jaszcz K, Nikitin Y, Tizzoni L, Wang JG, Staessen JA, et al. β-Adducin polymorphisms, blood pressure and sodium excretion in three European populations. Am J Hypertens 2003, 16:840-846. 10.1016/S0895-7061(03)00975-0, 14553963.
13. Cwynar M, Staessen JA, Tichá M, Nawrot T, Citterio L, Kuznetsova T, Wojciechowska W, Stolarz K, Filipovský J, Kawecka-Jaszcz K, et al. Epistatic interaction between α- and γ-adducin on influences peripheral and central pulse pressure in White Europeans. J Hypertens 2005, 23:961-969. 10.1097/01.hjh.0000166836.70935.e7, 15834281.
14. Kuznetsova T, Staessen JA, Thijs L, Kunath C, Olszanecka A, Ryabikov A, Tikhonoff V, Stolarz K, Bianchi G, Casiglia E, et al. Left ventricular mass in relation to genetic variation in angiotensin II receptors, renin system genes, and sodium excretion. Circulation 2004, 110:2644-2650. 10.1161/01.CIR.0000145541.63406.BA, 15492316.
15. Kuznetsova T, Manunta P, Casamassima N, Messaggio E, Jin Y, Thijs L, Richart T, Fagard RH, Bianchi G, Staessen JA. Left ventricular geometry and endogenous ouabain in a Flemish population. J Hypertens 2009, 27:1884-1891. 10.1097/HJH.0b013e32832e49a8, 19684520.
16. Dumas P, Kren V, Krenová D, Pravenec M, Hamet P, Tremblay J. Identification and chromosomal localization of ecogenetic components of electrolyte excretion. J Hypertens 2002, 20:209-217. 10.1097/00004872-200202000-00010, 11821705.
17. Cooper RS. Gene-environment interactions and the etiology of complex disease. Ann Intern Med 2003, 139:437-440.
18. Wang JG, Staessen JA, Messaggio E, Nawrot T, Fagard R, Hamlyn JM, Bianchi G, Manunta P. Salt, endogenous ouabain and blood pressure in the general population. J Hypertens 2003, 21:1475--1481. 10.1097/00004872-200308000-00010, 12872040.
19. Ferrandi M, Manunta P, Ferrari P, Bianchi G. The endogenous ouabain: molecular basis of its role in hypertension and cardiovascular complications. Front Biosci 2005, 10:2472-2477. 10.2741/1711, 15970509.
20. Manunta P, Messaggio E, Ballabeni C, Sciarrone MT, Lanzani C, Ferrandi M, Hamlyn JM, Cusi D, Galletti F, Bianchi G, et al. Plasma ouabain-like factor during acute and chronic changes in sodium balance in essential hypertension. Hypertension 2001, 38:198-203.